{"name":"Nanjing Yoko Biomedical Co., Ltd.","slug":"nanjing-yoko-biomedical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Control group: Oxiracetam Injection","genericName":"Control group: Oxiracetam Injection","slug":"control-group-oxiracetam-injection","indication":"Cognitive decline and memory impairment","status":"phase_3"},{"name":"Test group: L-oxiracetam Injection","genericName":"Test group: L-oxiracetam Injection","slug":"test-group-l-oxiracetam-injection","indication":"Cognitive impairment and memory disorders","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"G-CHOP","genericName":"G-CHOP","slug":"g-chop","indication":"Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Ncardipine Hydrochloride Injection","genericName":"Ncardipine Hydrochloride Injection","slug":"ncardipine-hydrochloride-injection","indication":"Acute hypertension management","status":"phase_3"}]}],"pipeline":[{"name":"Control group: Oxiracetam Injection","genericName":"Control group: Oxiracetam Injection","slug":"control-group-oxiracetam-injection","phase":"phase_3","mechanism":"Oxiracetam enhances neuronal membrane fluidity and increases oxygen utilization in the brain, promoting cognitive function and neuroprotection.","indications":["Cognitive decline and memory impairment","Stroke recovery and post-stroke cognitive dysfunction","Age-related cognitive disorders"],"catalyst":""},{"name":"G-CHOP","genericName":"G-CHOP","slug":"g-chop","phase":"phase_3","mechanism":"G-CHOP is a chemotherapy regimen combining gemcitabine, cyclophosphamide, doxorubicin, and vincristine (Oncovin) to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.","indications":["Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma)"],"catalyst":""},{"name":"Ncardipine Hydrochloride Injection","genericName":"Ncardipine Hydrochloride Injection","slug":"ncardipine-hydrochloride-injection","phase":"phase_3","mechanism":"Nicardipine hydrochloride is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure.","indications":["Acute hypertension management","Hypertensive emergency"],"catalyst":""},{"name":"Test group: L-oxiracetam Injection","genericName":"Test group: L-oxiracetam Injection","slug":"test-group-l-oxiracetam-injection","phase":"phase_3","mechanism":"L-oxiracetam enhances neuronal membrane fluidity and facilitates neurotransmitter function, potentially improving cognitive and neurological outcomes.","indications":["Cognitive impairment and memory disorders","Age-related cognitive decline","Cerebrovascular insufficiency"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxORndHY3daWUhJWEJGMnZieF93aEs4TW12UXkzV0QxVU1BR2NjZGtmVkhOV0lIZWw2a3o5Z1VMTW9DTnBJZUFIblRGMnJrUThVZk9Sa1Y1UnlIazhCTmx4RlpFTm1GLWNJXzNubGhWbldzQzFYcGN0MmhpZkItMXljYXNoV0RfZEJZeEx1MmxIcmZDd3VibllsOF9CZ0xYLV9ZR0d5U3F3TFRHMURrZmdZTWVzX0Jldkhyam5BVnR2V2h5eUxLbUJOTGxMQUpnb0s0TDBpVEV5Ni12eFQzc3o0R2hyVQ?oc=5","date":"2024-06-06","type":"pipeline","source":"prnewswire.com","summary":"Global Carotid Artery Stent Market to Grow Substantially at a CAGR of ~3% by 2030 | DelveInsight - prnewswire.com","headline":"Global Carotid Artery Stent Market to Grow Substantially at a CAGR of ~3% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQSWdSOHBwaGwtdE80eUJ4cVJteEg0VHE4M3hCdzNxcG5rQ05ZRU9LeUJGMEw4WU9tMnp0VXFib3lpUmJLenNJTl9kY2h6ZkNLdlVHSUx4WkhLa1BOSEwxcU5qR1FndXhPeFlHVDVLZUVlZWdENUJPWmhJMzhRR1RVcVVEWjhJV1pUZ0VGa29ZUDd6NnJEUU1jcDdYaVdzZ0txWkJjVUxiNUkzZllsek9oTk00dGVSakVKemFDa0xodGh5aDlXQ2xma0l5UUZ4azM1dnlfSDFPVnV2ZnBaQmc?oc=5","date":"2024-06-04","type":"pipeline","source":"prnewswire.com","summary":"Global Thrombectomy Devices Market to Witness Growth at a CAGR of ~5% by 2030 | DelveInsight - prnewswire.com","headline":"Global Thrombectomy Devices Market to Witness Growth at a CAGR of ~5% by 2030 | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}